Addressing overdiagnosis and overtreatment in cancer: A prescription for change

The Lancet Oncology

Volumn 15, Issue 6, 2014, Pages

  Esserman, Laura J ^a   Thompson, Ian M ^b   Reid, Brian ^c   Nelson, Peter ^c   Ransohoff, David F ^d   Welch, H Gilbert ^e   Hwang, Shelley ^f   Berry, Donald A ^g   Kinzler, Kenneth W ^h   Black, William C ⁱ   Bissell, Mina ^j   Parnes, Howard ^k   Srivastava, Sudhir ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e DARTMOUTH COLLEGE   (United States)

^f DUKE UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^j LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER SCREENING; CLINICAL PRACTICE; DYSPLASTIC NEVUS; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; INTRADUCTAL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NOTE; PRECANCER; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; THYROID CANCER; TUMOR INVASION;

EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS; PRECANCEROUS CONDITIONS; TERMINOLOGY AS TOPIC;

EID: 84899752622     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70598-9     Document Type: Note

References (81)

1. Esserman L, Shieh Y, Thompson I Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302:1685-1692.
2. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
3. Shibata D Cancer. Heterogeneity and tumor history. Science 2012, 336:304-305.
4. Esserman LJ, Berry DA, Cheang MC, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012, 132:1049-1062.
5. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012, 30:2601-2608.
6. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas.
7. Autier P, Esserman LJ, Flowers CI, Houssami N Breast cancer screening: the questions answered. Nat Rev Clin Oncol 2012, 9:599-605.
8. Welch HG, Black WC Overdiagnosis in cancer. J Natl Cancer Inst 2010, 102:605-613.
9. Esserman LJ, Thompson IM, Reid B Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013, 310:797-798.
10. Domchek SMFT, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
11. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
12. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010, 183:1792-1796.
13. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002, 346:1041-1046.
14. Bissell MJ, Hines WC Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17:320-329.
15. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012, 30:3242-3249.
16. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
17. Thompson IM, Tangen CM Prostate cancer-uncertainty and a way forward. N Engl J Med 2012, 367:270-271.
18. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB Computed tomography screening and lung cancer outcomes. JAMA 2007, 297:953-961.
19. Bach PB Is our natural-history model of lung cancer wrong?. Lancet Oncol 2008, 9:693-697.
20. Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 2013, 159:411-420.
21. SEER Cancer Statistics Review (CSR) 1975-2009 National Cancer, Surveillance, Epidemiology and End Results (SEER)Surveillance, Epidemiology and End Results (SEER), (accessed Nov 14, 2012). http://seer.cancer.gov/csr/1975_2010/.
22. Davies L, Welch HG Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167.
23. Harach HR, Franssila KO, Wasenius VM Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985, 56:531-538.
24. Mazzaferri EL Managing small thyroid cancers. JAMA 2006, 295:2179-2182.
25. Cronan JJ Thyroid nodules: is it time to turn off the US machines?. Radiology 2008, 247:602-604.
26. Delongchamps NB, Singh A, Haas GP The role of prevalence in the diagnosis of prostate cancer. Cancer Control 2006, 13:158-168.
27. Cooperberg MR, Broering JM, Carroll PR Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010, 28:1117-1123.
28. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
29. Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabbagh R, Pépin J Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?. Eur Urol 2012, 62:453-459.
30. Thompson IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013, 369:603-610.
31. Manser RL, Dodd M, Byrnes G, Irving LB, Campbell DA Incidental lung cancers identified at coronial autopsy: implications for overdiagnosis of lung cancer by screening. Respir Med 2005, 99:501-507.
32. McFarlane MJ, Feinstein AR, Wells CK, Chan CK The 'epidemiologic necropsy'. Unexpected detections, demographic selections, and changing rates of lung cancer. JAMA 1987, 258:331-338.
33. Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst 2006, 98:748-756.
34. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409. for the National Lung Screening Trial Research.
35. Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014, 174:269-274. for the NLST Overdiagnosis Manuscript Writing.
36. Woloshin S, Schwartz LM, Black WC, Kramer BS Cancer screening campaigns-getting past uninformative persuasion. N Engl J Med 2012, 367:1677-1679.
37. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012, 379:823-832.
38. Bleyer A, Welch HG Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012, 367:1998-2005.
39. Odom SR, Duffy SD, Barone JE, Ghevariya V, McClane SJ The rate of adenocarcinoma in endoscopically removed colorectal polyps. Am Surg 2005, 71:1024-1026.
40. Esserman LJ, Shieh Y, Rutgers EJ, et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 2011 Dec, 130:725-734.
41. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
42. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98:1183-1192. the TRANSBIG.
43. Fyles AMD, Pintilie M, Shi W, et al. Luminal A subtype predicts radiation response in patients with T1N0 breast cancer enrolled in a randomized trial of tamoxifen with or without breast radiation. 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 6-10, 2011. Abstract S2-2.
44. Coopey SB, Buckley JM, Smith BL, Hughes KS, Gadd MA, Specht MC Lumpectomy cavity shaved margins do not impact re-excision rates in breast cancer patients. Ann Surg Oncol 2011, 18:3036-3040.
45. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013, 31:2382-2387.
46. Flowers CI, O'Donoghue C, Moore D, et al. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention. Breast Cancer Res Treat 2013, 139:769-777.
47. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med 2011, 155:481-492.
48. Esserman L, Cowley H, Eberle C, et al. Improving the accuracy of mammography: volume and outcome relationships. J Natl Cancer Inst 2002, 94:369-375.
49. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993, 328:901-906.
50. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
51. Linos E, Parvataneni R, Stuart SE, Boscardin WJ, Landefeld CS, Chren MM Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer. JAMA Intern Med 2013, 173:1006-1012.
52. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010, 146:283-287.
53. Rogers HW, Coldiron BM Analysis of skin cancer treatment and costs in the United States Medicare population, 1996-2008. Dermatol Surg 2013, 39:35-42.
54. Welch HG, Woloshin S, Schwartz LM Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005, 331:481.
55. Levell NJ, Beattie CC, Shuster S, Greenberg DC Melanoma epidemic: a midsummer night's dream?. Br J Dermatol 2009, 161:630-634.
56. Geller AC, Clapp RW, Sober AJ, et al. Melanoma epidemic: an analysis of six decades of data from the connecticut tumor registry. J Clin Oncol 2013, 31:4172-4178.
57. O'Donoghue C, Eklund M, Ozanne EM, Esserman LJ Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med 2014, 160:145-153.
58. Reid BJ, Li X, Galipeau PC, Vaughan TL Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010, 10:87-101.
59. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091.
60. Wang KK, Sampliner RE Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797. the Practice Parameters Committee of the American College of.
61. Sanaka MR, Super DM, Feldman ES, Mullen KD, Ferguson DR, McCullough AJ Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc 2006, 63:97-103.
62. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg 1985, 150:44-51.
63. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 2011, 129:165-173.
64. Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 2009, 27:1362-1367.
65. Gomez SL, Lichtensztajn D, Kurian AW, et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. J Clin Oncol 2010, 28:e155-e157.
66. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010, 102:627-637.
67. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013, 105:701-710.
68. Omer ZHE, Esserman LJ, Ozanne EM. Words matter: influence of DCIS diagnosis terminology on patient treatment decisions. 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 6-10, 2011. Poster P5-15-01.
69. MEDICARE: action needed to address higher utilization of anatomic pathology services by those who self-refer. GAO-13-445, June 24, 2013 2013, United States Government Accountability, United States Government Accountability Office, Washington, DC.
70. Chang WY, Huang A, Yang CY, et al. Computer-aided diagnosis of skin lesions using conventional digital photography: a reliability and feasibility study. PLoS One 2013, 8:e76212.
71. Baldwin LM, Trivers KF, Matthews B, et al. Vignette-based study of ovarian cancer screening: do US physicians report adhering to evidence-based recommendations?. Ann Intern Med 2012, 156:182-194.
72. Ransohoff DF, McNaughton Collins M, Fowler FJ Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 2002, 113:663-667.
73. Epstein JI, Amin MB, Reuter VR, Mostofi FK The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998, 22:1435-1448. the Bladder Consensus Conference.
74. Kolata G. 'Cancer' or 'weird cells': which sounds deadlier? The New York Times (New York, NY), Nov 21, 2011.
75. Towards precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease 2011, Committee on a Framework for Developing a New Taxonomy of, National Academies Press, Washington, DC.
76. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
77. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007, 4:e67.
78. Stamatakis L, Siddiqui MM, Nix JW, et al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer 2013, 119:3359-3366.
79. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98:529-534.
80. Parker-Pope T. Overtreatment is taking a harmful toll. The New York Times (New York, NY), Aug 27, 2012.
81. Pienta KJ, McGregor N, Axelrod R, Axelrod DE Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 2008, 1:158-164.